1 day ago
Ozempic isn't just for weight loss. A new study says it may reverse signs of fatty liver disease, too.
Cbsnews.com and 1 more

Vote NaN
References
ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM
0 Comments
Be the first to comment
Add your thoughts and get the conversation going.
Related Articles
Explore Your Interests
Create an account and enjoy content that interests you with your personalized feed
Unlimited Access
Personalized Feed
Full Experience
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.